A Multiple Dose Study of Repeat Intravitreal Injections of GEM103 in Dry Age-related Macular Degeneration

NCT04643886 · clinicaltrials.gov ↗

PHASE2

Phase

TERMINATED

Status

62

Enrollment

INDUSTRY

Sponsor class

Stopped no further benefit

Conditions

Dry Age-related Macular Degeneration
Geographic Atrophy
Macular Degeneration
Retinal Disease
Retinal Degeneration

Interventions

DRUG: GEM103

Sponsor

Gemini Therapeutics, Inc.